- Home
- EPSN vs MNPR Comparison
EPSN vs MNPR Comparison
Compare EPSN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- MNPR
- Stock Information
- Founded
- EPSN 2005
- MNPR 2014
- Country
- EPSN Canada
- MNPR United States
- Employees
- EPSN N/A
- MNPR N/A
- Industry
- EPSN Oil & Gas Production
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- EPSN Energy
- MNPR Health Care
- Exchange
- EPSN Nasdaq
- MNPR Nasdaq
- Market Cap
- EPSN 129.8M
- MNPR 113.5M
- IPO Year
- EPSN N/A
- MNPR 2019
- Fundamental
- Price
- EPSN $5.87
- MNPR $30.68
- Analyst Decision
- EPSN Strong Buy
- MNPR Strong Buy
- Analyst Count
- EPSN 1
- MNPR 3
- Target Price
- EPSN $7.00
- MNPR $27.33
- AVG Volume (30 Days)
- EPSN 23.5K
- MNPR 93.6K
- Earning Date
- EPSN 11-06-2024
- MNPR 11-08-2024
- Dividend Yield
- EPSN 4.41%
- MNPR N/A
- EPS Growth
- EPSN N/A
- MNPR N/A
- EPS
- EPSN 0.24
- MNPR N/A
- Revenue
- EPSN $31,145,315.00
- MNPR N/A
- Revenue This Year
- EPSN N/A
- MNPR N/A
- Revenue Next Year
- EPSN $15.65
- MNPR N/A
- P/E Ratio
- EPSN $23.77
- MNPR N/A
- Revenue Growth
- EPSN N/A
- MNPR N/A
- 52 Week Low
- EPSN $4.70
- MNPR $1.55
- 52 Week High
- EPSN $6.20
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- EPSN 50.14
- MNPR 76.63
- Support Level
- EPSN $5.67
- MNPR $20.16
- Resistance Level
- EPSN $6.15
- MNPR $25.97
- Average True Range (ATR)
- EPSN 0.21
- MNPR 2.75
- MACD
- EPSN 0.01
- MNPR 0.41
- Stochastic Oscillator
- EPSN 56.25
- MNPR 90.25
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.